<DOC>
	<DOCNO>NCT01498458</DOCNO>
	<brief_summary>Angiogenesis essential growth large tumor . A number anti-angiogenic agent currently development . Bevacizumab , humanise monoclonal antibody vascular endothelial growth factor ( VEGF ) , show improve disease free survival first line metastatic breast cancer associate chemotherapy 1 . Results randomise phase II trial combine sorafenib , tyrosine kinase inhibitor target multiple tyrosine kinase include VEGFR1 , VEGFR2 , VEGFR3 , capecitabine recently report 2 . Compared capecitabine plus placebo , progression-free survival capecitabine + sorafenib arm significantly increase 4.1 month 6.4 month . Toxicities also increase , incidence rate grade 3/4 hand foot syndrome 45 % capecitabine + sorafenib arm compare 13 % capecitabine + placebo arm . The increased toxicity likely limit clinical use regimen . Pazopanib potent , multi-targeted TKI VEGFR-1 , -2 , -3 , PDGFR-α -β c-kit recently approve treatment renal cell cancer U.S . In EU , positive opinion issue European Medicines Agency . A phase II study GW786034 ( pazopanib ) patient recurrent metastatic invasive breast carcinoma include 19 patient maximum 2 line chemotherapy advance disease 3 . Pazopanib 800 mg daily give continuously . A clinically significant rate stable disease ( 58 % ) detect median TTP 5.3 month ( 95 % CI : 1.8 - 9.0 month ) . Four patient treat pazopanib SD ≥ 6 month , clinical benefit rate ( CBR ) , define rate SD ≥ 6 month CR PR , 5/19 ( 26 % ) , least comparable sunitinib bevacizumab ( CBR 16 % 17 % , respectively ) . The pivotal study full dose ( 800 mg ) daily pazopanib renal cell cancer report hand foot syndrome grade 6 % patient 4 . The optimally tolerate regimen ( OTR ) pazopanib determine administer combination capecitabine oxaliplatin patient advance CRC 5 . In patient receive capecitabine ( 850 mg twice daily ) plus 800 mg daily pazopanib combine oxaliplatin , incidence hand foot syndrome grade 24 % . The present study investigate combination pazopanib capecitabine advance metastatic breast cancer aim develop new treatment option increase efficacy tolerability .</brief_summary>
	<brief_title>Pazopanib Combination With Capecitabine Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>Primary Objective : To assess maximum tolerate dose ( MTD ) pazopanib combination capecitabine treatment metastatic HER2-negative breast cancer . Secondary Objective : 1 . To determine dose-limiting toxicity ( DLT ) . 2 . To determine compliance toxicity combination . 3 . To determine objective response rate ( ORR ) clinical benefit rate ( CBR ) patient measurable disease . 4 . To determine duration response . 5 . To determine progression-free survival ( PFS ) . 6 . To determine predictive value response serum marker VEGF .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Written inform consent study procedure accord local regulatory requirement prior begin specific protocol procedure . Complete baseline documentation must submit via webbased data collection system MedCODES GBG Forschungs GmbH . Diagnosis advance metastatic HER2negative breast cancer . HER2negative define HercepTest IHC 02+ FISH negative ( ratio &lt; 2.2 ) . At least one prior endocrine one noncapecitabinecontaining chemotherapy treatment metastatic/advanced disease . Documented progression either measurable , nonmeasurable lesion accord RECIST criterion , new lesion . Complete radiological clinical tumor assessment within 4 week prior registration perform clinically indicate . Age = &gt; 18 year . Karnofsky Performance Status index = &gt; 60 % . Laboratory requirement : Absolute neutrophil count ( ANC ) = &gt; 1.5 x 109/L , Platelets = &gt; 100 x 109/L , Hemoglobin = &gt; 9 g/dL ( = &gt; 5.6 mmol/L ) , Prothrombin time ( PT ) international normalise ratio ( INR ) = &lt; 1.2x UNL ( upper normal limit ) , Partial thromboplastin time ( PTT ) = &lt; 1.2x UNL , Total bilirubin &lt; 1.5x UNL , ASAT ( SGOT ) ALAT ( SGPT ) = &lt; 2.5x UNL ( concomitant elevation serum bilirubin ASAT/ALAT 1.0x UNL permit ) , The calculated creatinine clearance = &gt; 50 mL/min ) , Urine Protein Creatinine Ratio ( UPC ) &lt; 1 ( UPC = &gt; 1 , 24hour urine protein must &lt; 1 g ) . Normal cardiac function confirm ECG ; correct QT interval ( QTc ) &lt; 480 msec use Bazett 's formula . A female either : Nonchildbearing potential i.e. , physiologically incapable become pregnant history hysterectomy , bilateral oophorectomy ( ovariectomy ) , bilateral tubal ligation postmenopausal status . Childbearing potential negative serum pregnancy test within 2 week prior registration , preferably close first dose possible , agree use adequate contraception . Acceptable contraceptive method , use consistently accordance product label instruction physician , follow : An intrauterine device document failure rate le 1 % per year , Vasectomised partner sterile prior female subject 's entry sole sexual partner female , Complete abstinence sexual intercourse 14 day exposure investigational product , dose period , least 21 day last dose investigational product , Doublebarrier contraception ( condom spermicidal jelly , foam suppository , film ; diaphragm spermicide ; male condom diaphragm spermicide ) . Female subject lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . Known suspected hypersensitivity reaction investigational compound incorporated substance . Last metastatic treatment capecitabine , 5FU , bevacizumab , sunitinib , sorafenib , antibody tyrosine kinase inhibitor antiangiogenic activity . Investigational therapy within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib . Any ongoing toxicity prior anticancer therapy grade &gt; 1 and/or progress severity , except alopecia . Surgery tumor embolisation within 28 day prior first dose pazopanib . At least 4 week since radiotherapy , full recovery . The measurable disease must completely outside radiated field must pathological proof progressive disease . Concurrent immunobiological hormonal therapy cancer . History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug . Life expectancy le 3 month . History thyroid autoimmune disease thyroid disorder thyroid value standard range Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding include , limited : Active peptic ulcer disease , Known intraluminal metastatic lesion/s risk bleeding , Inflammatory bowel disease ( e.g . ulcerative colitis , Crohn 's disease ) , gastrointestinal condition increase risk perforation , History abdominal fistula , gastrointestinal perforation , intra abdominal abscess within 28 day prior begin study treatment . Severe liver dysfunction Grade 3 4 diarrhea . Clinically significant gastrointestinal abnormality may affect absorption investigational product include , limited : Malabsorption syndrome , Major resection stomach small bowel . Presence uncontrolled infection . History one follow cardiovascular condition within past 6 month : Cardiac angioplasty stenting , Myocardial infarction , Unstable angina , Coronary artery bypass graft surgery , Symptomatic peripheral vascular disease , Class III IV congestive heart failure , define New York Heart Association ( NYHA ) , Poorly control hypertension ( define systolic blood pressure [ SBP ] ≥ 160 mmHg diastolic blood pressure [ DBP ] ≥ 90 mmHg ) . Note : Initiation adjustment antihypertensive medication ( ) permit prior study entry . BP must reassess two occasion separate minimum 1 hour ; occasion , mean ( 3 reading ) SBP/DBP value BP assessment must &lt; 160/95 mmHg order subject eligible study ( see Section 9.6.1 detail BP control reassessment prior study enrollment ) . History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible . Evidence active bleeding bleed diathesis include , limited : Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer ( procedure catheter placement consider major ) , Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel , Hemoptysis prior 6 week first dose study drug , Blood transfusion within 7 day study entry . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>German Breast Group</keyword>
	<keyword>GBG Forschungs GmbH</keyword>
	<keyword>GBG</keyword>
	<keyword>GBG 62</keyword>
	<keyword>PazoX</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
</DOC>